Dobutamine

beta-Adrenergic Agonist — CARDIOVASCULAR SYSTEM

Key facts

Dobutamine is an ofp drug in the beta-Adrenergic Agonist class catalogued in DrugCentral. It was first approved by the FDA in 1978. Its mechanism of action is classified as Adrenergic beta-Agonists. DrugCentral lists 31 molecular targets, including ADRA1D, Adra1a and SLC6A3. Recorded indications include Cardiac Decompensation, Cardiac Decompensation Post Cardiac Surgery, Cardiogenic shock and Decompensated cardiac failure.

• Approval status: ofp (first approved 1978 by the FDA).
• Drug class: beta-Adrenergic Agonist.
• Mechanism of action: Adrenergic beta-Agonists.
• Molecular targets: ADRA1D, Adra1a, SLC6A3 and Adra1b (31 listed in DrugCentral).
• Indications: Cardiac Decompensation, Cardiac Decompensation Post Cardiac Surgery, Cardiogenic shock, Decompensated cardiac failure and Organic Cardiac Disease and others.
• ATC code: C01CA07 (Adrenergic and dopaminergic agents).
• Molecular formula: C18H23NO3; molecular weight 301.39 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (6)

• Cardiac Decompensation
• Cardiac Decompensation Post Cardiac Surgery
• Cardiogenic shock
• Decompensated cardiac failure
• Organic Cardiac Disease
• Stress echocardiography using dobutamine

Contraindications (8)

• Aortic valve stenosis
• Atrial fibrillation
• Hypertensive disorder
• Hypokalemia
• Hypovolemia
• Idiopathic hypertrophic subaortic stenosis
• Myocardial infarction
• Ventricular premature beats

Mechanism & targets

• Mechanism of action (MoA): Adrenergic beta-Agonists
• Established pharmacologic class: beta-Adrenergic Agonist

Molecular targets (31)

Target	Gene	Action	Activity
Alpha-1D adrenergic receptor	ADRA1D	unknown	Ki 7.35
Alpha-1A adrenergic receptor	Adra1a	unknown	IC50 6.96
Sodium-dependent dopamine transporter	SLC6A3	unknown	Ki 6.91
Alpha-1B adrenergic receptor	Adra1b	unknown	Ki 6.73
Sodium-dependent noradrenaline transporter	SLC6A2	unknown	Ki 6.42
Carbonic anhydrase 15	Ca15	unknown	Ki 6.41
Carbonic anhydrase 2	CA2	unknown	Ki 6.32
Arachidonate 15-lipoxygenase	ALOX15	unknown	IC50 6.22
Beta-2 adrenergic receptor	ADRB2	agonist	EC50 6.20
Carbonic anhydrase 5A, mitochondrial	CA5A	unknown	Ki 6.14
Carbonic anhydrase 5B, mitochondrial	CA5B	unknown	Ki 6.05
Sodium-dependent serotonin transporter	SLC6A4	unknown	Ki 6.00
Sigma non-opioid intracellular receptor 1	SIGMAR1	unknown	Ki 5.98
Alpha-2B adrenergic receptor	ADRA2B	unknown	Ki 5.87
Membrane-associated progesterone receptor component 1	Pgrmc1	unknown	Ki 5.80
D(3) dopamine receptor	DRD3	unknown	Ki 5.77
Carbonic anhydrase 1	CA1	unknown	Ki 5.72
Beta-1 adrenergic receptor	ADRB1	agonist	EC50 5.50
Tyrosine-protein kinase Fyn	FYN	unknown	IC50 5.40
Solute carrier family 22 member 1	SLC22A1	unknown	IC50 5.38

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1978-07-18	FDA	—	—

ATC classification

ATC code	Therapeutic hierarchy
C01CA07	CARDIOVASCULAR SYSTEM › CARDIAC THERAPY › CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES › Adrenergic and dopaminergic agents

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Appendicolith	919.2
Multiple organ dysfunction syndrome	800.1
Appendicitis	747.7
Ventricular fibrillation	642.6
Blood phosphorus increased	501.3
Ascites	497.3
Stress	482.4
Myasthenia gravis	427.2
Hyperphosphataemia	405.9
Analgesic therapy	372.8
Sleep disorder therapy	364.7
Abdominal distension	347.6

Chemical structure

• Molecular formula: C₁₈H₂₃NO₃
• Molecular weight: 301.39 g/mol
• CAS number: —
• InChIKey: JRWZLRBJNMZMFE-UHFFFAOYSA-N
• PubChem CID: 36811

CC(CCC1=CC=C(O)C=C1)NCCC1=CC=C(O)C(O)=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Dobutamine used for?

DrugCentral lists the following indications for Dobutamine: Cardiac Decompensation, Cardiac Decompensation Post Cardiac Surgery, Cardiogenic shock, Decompensated cardiac failure, Organic Cardiac Disease and Stress echocardiography using dobutamine.

How does Dobutamine work?

Dobutamine is classified as Adrenergic beta-Agonists; its molecular targets in DrugCentral include ADRA1D, Adra1a, SLC6A3 and Adra1b.

When was Dobutamine first approved?

Dobutamine was first approved by the FDA in 1978.

What drug class does Dobutamine belong to?

Dobutamine is in the beta-Adrenergic Agonist class.

What is the chemical formula of Dobutamine?

Dobutamine has the molecular formula C18H23NO3 and a molecular weight of 301.39 g/mol.

Sources

• DrugCentral drug card 937 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1200418 — compound record and bioactivity
• PubChem CID 36811 — chemical identifiers
• DrugBank DB00841 — drug record
• FDA UNII 3S12J47372 — substance identity
• DailyMed: FDA labels for Dobutamine — current prescribing information (label search)
• UniProt P25100 (ADRA1D) — target protein
• UniProt Q01959 (SLC6A3) — target protein
• UniProt P23975 (SLC6A2) — target protein
• UniProt P00918 (CA2) — target protein
• UniProt P07550 (ADRB2) — target protein
• UniProt P35218 (CA5A) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.